ABC:NYE-AmerisourceBergen Corporation (USD)

COMMON STOCK | Medical Distribution | NYE

Last Closing Price

USD 97.21

Change

-1.09 (-1.11)%

Market Cap

USD 19.99B

Volume

0.89M

Average Target Price

USD 99.00 (+1.84%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; offers specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets, as well as provides demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MCK McKesson Corporation

-1.23 (-0.84%)

USD24.02B 30.61 13.02
CAH Cardinal Health, Inc

+0.07 (+0.14%)

USD14.66B 11.87 7.59
PBH Prestige Consumer Healthcare I..

-0.33 (-0.90%)

USD1.84B 13.01 11.01
OMI Owens & Minor, Inc

+0.15 (+1.98%)

USD0.48B 15.10 11.34
7459 Medipal Holdings Corp

N/A

N/A N/A N/A

ETFs Containing ABC

Symbol Name Weight Mer Price(Change) Market Cap
FXG First Trust Consumer Stap.. 3.94 % 0.64 %

-0.32 (-0.68%)

USD0.25B
FHC:CA FT AlphaDEX U.S. Consumer.. 3.86 % 0.70 %

N/A

USD3.48M
FHC-F:CA FT AlphaDEX U.S. Consumer.. 3.86 % 0.70 %

N/A

N/A
XHS SPDR S&P Health Care Serv.. 2.88 % 0.35 %

-0.21 (-0.31%)

USD0.09B
RWL Invesco S&P 500 Revenue E.. 1.82 % 0.39 %

+0.07 (+0.14%)

USD0.73B
FLAG FLAG-Forensic Accounting .. 1.74 % 1.44 %

N/A

USD4.83M
RPV Invesco S&P 500 Pure Valu.. 1.71 % 0.35 %

+0.12 (+0.26%)

USD0.52B
ESGF Invesco Global ESG Revenu.. 0.73 % 0.45 %

N/A

USD0.02B
UCC ProShares Ultra Consumer .. 0.00 % 0.95 %

+2.34 (+1.97%)

USD0.02B
RWDC Direxion MSCI Defensives .. 0.00 % 0.46 %

N/A

USD7.11M
SPXT ProShares S&P 500 ex-Tech.. 0.00 % 0.27 %

+0.23 (+0.43%)

USD2.69M
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.61 %

+0.09 (+0.65%)

USD0.73M
SPXN ProShares S&P 500 ex-Fina.. 0.00 % 0.27 %

+0.41 (+0.60%)

USD4.31M
RALS ProShares RAFI Long/Short 0.00 % 0.95 %

-0.11 (-0.36%)

USD5.37M
SSO ProShares Ultra S&P500 0.00 % 0.90 %

+2.00 (+1.55%)

USD2.15B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Distribution)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.34% 80% B- 90% A-
Dividend Return 0.99% 75% C 44% F
Total Return 15.33% 80% B- 90% A-
Trailing 12 Months  
Capital Gain 10.18% 60% D- 84% B
Dividend Return 1.86% 75% C 45% F
Total Return 12.04% 60% D- 84% B
Trailing 5 Years  
Capital Gain -10.70% 100% A+ 43% F
Dividend Return 6.86% 50% F 24% F
Total Return -3.84% 100% A+ 35% F
Average Annual (5 Year Horizon)  
Capital Gain -0.35% 100% A+ 19% F
Dividend Return 1.74% 50% F 38% F
Total Return 1.39% 100% A+ 17% F
Risk Return Profile  
Volatility (Standard Deviation) 13.24% 60% D- 56% F
Risk Adjusted Return 10.46% 100% A+ 15% F
Market Capitalization 19.99B 80% B- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Distribution)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.15 60% D- 61% D-
Price/Book Ratio 5.67 40% F 13% F
Price / Cash Flow Ratio 8.53 20% F 37% F
EV/EBITDA 12.71 40% F 40% F
Management Effectiveness  
Return on Equity 47.22% 100% A+ 96% A
Return on Invested Capital 26.58% 100% A+ 95% A
Return on Assets 2.86% 60% D- 58% F
Debt to Equity Ratio 140.12% 60% D- 22% F
Technical Ratios  
Short Ratio 2.77 60% D- 32% F
Short Percent 2.51% 60% D- 67% D+
Beta 0.62 80% B- 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.